NPM1 and acute myeloid leukemia: The ongoing KOMET-008 trial is an open-label dose-escalation and expansion study aiming to determine the safety, tolerability, and preliminary efficacy of Ziftomenib in association with standard-of-care regimens for the treatment of either R/R NPM1-mutant AML (arm A) or KMT2A-rearranged AML (arm B).